Missouri Roundup Lawsuit After the Supreme Court — What Bayer’s Win Really Means for Your Cancer Case
You heard the news and your stomach dropped. The Supreme Court sided with Bayer. Your Roundup case — the one built on years of spraying that weedkiller in your yard, at your job, on the farm, and then hearing a doctor say the words “non-Hodgkin lymphoma” — feels like it just vanished in a 7-2 vote. Take a breath. It did not vanish. One legal theory is gone. Three others survived. And Bayer is still paying $7.25 billion to settle thousands of cases — a company does not write a check that size if it believes the remaining claims have no teeth.
We are Attorney911 — The Manginello Law Firm. We handle toxic-tort and catastrophic-injury cases, and we take cases in Missouri. What follows is the honest, complete picture of where Roundup litigation stands after June 25, 2026, what the ruling took away, what it left alive, and what you should do about it — whether you have a pending case, think you might have one, or are staring at a settlement opt-out deadline that already passed.
What the Supreme Court Actually Did on June 25, 2026
The justices overturned a $1.25 million jury verdict from a Missouri state court — a verdict won by a man who developed non-Hodgkin lymphoma after years of glyphosate exposure through Roundup. The Supreme Court ruled 7-2 that his claim — and the same claim in approximately 65,000 other pending lawsuits nationwide — could not proceed under a state-law theory that Bayer failed to warn about cancer risk on the product’s label.
The legal engine behind the ruling is the Federal Insecticide, Fungicide, and Rodenticide Act — known as FIFRA. FIFRA governs how pesticides are registered, labeled, and sold in the United States. Under FIFRA, the EPA approved Roundup’s label after reviewing the active ingredient glyphosate and determining that it is “not likely to be carcinogenic to humans.” The EPA did not require a cancer warning on the label. FIFRA also contains a provision that prohibits states from imposing labeling requirements different from, or in addition to, those approved by the EPA.
The Supreme Court held that because the EPA approved Roundup’s label without requiring a cancer warning, state-law claims arguing that Bayer should have added one are expressly preempted — meaning federal law overrides and eliminates those state-law claims. The Court deferred to the EPA’s regulatory determination as the controlling federal position.
The EPA, under FIFRA authority, approved Roundup’s label after determining that glyphosate is “not likely to be carcinogenic to humans,” and declined to require a cancer warning. The Supreme Court’s preemption analysis rests on the FIFRA provision that prohibits states from imposing labeling requirements different from or additional to those approved by the EPA.
Here is what that ruling did NOT do. It did not find that glyphosate is safe. It did not find that Roundup does not cause cancer. It did not dismiss all 65,000 lawsuits. It did not change the $7.25 billion settlement. And it did not end the litigation. It eliminated one legal theory — the easiest one to prove — and left three others standing.
The Theory That Is Dead: Failure-to-Warn
Failure-to-warn was the workhorse theory of Roundup litigation. It was generally considered the easiest to prove because it did not require showing that the product was defectively designed or that the company lied — only that the label should have carried a cancer warning and did not. Most of the 65,000 pending lawsuits included a failure-to-warn claim as part of their complaint.
That theory is now preempted nationwide. Regardless of the state, regardless of the venue, regardless of how strong your exposure evidence is — you can no longer sue Bayer or Monsanto for failing to put a cancer warning on the Roundup label. The EPA’s determination that no such warning is required controls, and FIFRA’s express preemption clause makes state-law failure-to-warn claims invalid.
This is a significant setback. There is no honest way to frame it otherwise. The loss of failure-to-warn removes the legal theory with the highest probability of success, and it gives Bayer a powerful regulatory shield — the EPA’s own finding — to wave in front of every jury in every remaining case.
But it is not the end of the case. It is the end of one road. Three others remain open.
The Three Theories That Survive
The Supreme Court’s ruling addresses label warnings. It does not address every way a company can be held accountable for a product that causes harm. Three legal theories survived the ruling, and each attacks a different aspect of Bayer’s conduct:
Negligence. Plaintiffs allege that Bayer and Monsanto breached a duty of reasonable care in designing, testing, and marketing Roundup. This theory does not depend on what the label said — it depends on what the company did in its laboratories, its boardrooms, and its testing protocols. Did Monsanto conduct adequate long-term studies? Did it monitor post-market safety signals? Did it respond appropriately when the International Agency for Research on Cancer classified glyphosate as “probably carcinogenic to humans” in 2015? These questions do not touch the label, and the preemption ruling does not foreclose them. Discovery in a negligence case targets internal testing protocols, corporate knowledge of carcinogenicity signals, and post-market surveillance records.
Misrepresentation and fraudulent marketing. Plaintiffs allege that Bayer misrepresented Roundup’s safety in marketing materials, advertising, and public statements that went beyond the product label. The Supreme Court’s preemption ruling addresses what the label said — not what the company told consumers in advertisements, on its website, in press releases, or through industry-funded research campaigns. If Monsanto’s marketing materials said Roundup was safe enough to “spray it without a worry” while internal documents show scientists raising concerns about cancer risk, that gap is a misrepresentation claim — and it is not preempted. Internal documents showing discrepancies between public safety claims and internal scientific concerns are the critical discovery targets. This may be the strongest surviving theory because it attacks what the company said, not what the label omitted.
Design defect. Plaintiffs allege that Roundup was defectively designed because its formulation unreasonably endangered users. This theory challenges the product itself — the chemical formulation, the concentration of glyphosate, the decision not to use a safer alternative — rather than the label. It is not directly foreclosed by the preemption ruling, which was about labeling requirements, not product design. But this is where the next fight will happen. Bayer is expected to argue that the preemption logic should extend to design-defect claims, on the theory that if the EPA approved the product as formulated, state courts should not be allowed to second-guess that approval through design-defect claims. Whether that argument succeeds is an open question — and it is one of the most important unresolved legal issues in the Roundup litigation today.
The honest assessment: each of these surviving theories is harder to prove than failure-to-warn was. They require deeper expert proof on general causation (does glyphosate cause non-Hodgkin lymphoma?) and specific causation (did THIS plaintiff’s cancer come from Roundup exposure?). They require more complex discovery into corporate conduct. And they face a defense that now has the Supreme Court’s blessing to argue that the federal regulator found no cancer risk. But they are alive, they are viable, and they are being pursued.
The $7.25 Billion Settlement — Where It Stands
In February 2026 — after the Supreme Court had agreed to hear Bayer’s appeal but before the ruling came down — Bayer announced a $7.25 billion settlement with attorneys seeking to represent a nationwide class of people who say Roundup exposure caused their cancer. The deal is aimed at resolving most of the remaining lawsuits, as well as potential claims from people who were exposed to Roundup and develop cancer in the future.
In March 2026, a state court judge in Missouri gave initial approval to the proposed settlement. The settlement is proceeding through Missouri state court — the same jurisdiction that produced the now-overturned jury verdict, making Missouri the procedural epicenter of the nationwide Roundup litigation landscape.
The Supreme Court’s ruling does not change the terms of the settlement. Bayer has said it remains committed to moving forward with the deal. The settlement provides a guaranteed recovery track for class members — meaning people who stay in the class will receive compensation regardless of the Supreme Court’s ruling, and regardless of whether their individual case would have survived on the remaining legal theories.
But the settlement is not final. Several people have objected to the deal. The Missouri judge will consider final approval at a future court hearing. And the plaintiffs were given a June 4 deadline to decide whether to opt out of the settlement and pursue their individual cases in court — forcing them to choose whether to settle without knowing the Supreme Court’s final decision.
Did You Miss the June 4 Opt-Out Deadline?
This is the question that keeps people up at night, and the answer depends on which side of the line you fell on.
If you did NOT opt out by June 4 — you are in the class. Your case will be resolved through the settlement structure. You will receive compensation according to the settlement matrix, which allocates payments based on factors like exposure duration, cancer subtype, age at diagnosis, and treatment costs. You will not have to prove your case in court. You will not face the risk of the Supreme Court ruling. But you also will not have the opportunity for a higher individual recovery through trial. Lower-tier claims may recover in the tens of thousands, while higher-tier claims with prolonged occupational exposure and severe disease could reach several hundred thousand through the settlement structure.
If you DID opt out by June 4 — you are on your own. You kept your individual case. You made that decision without knowing the Supreme Court would rule against failure-to-warn three weeks later. You now face a harder road — but not an impossible one. Your case proceeds on the surviving theories: negligence, misrepresentation, and design defect. The probability of success has decreased with the loss of failure-to-warn, but the ceiling is higher. Individual litigation on surviving theories can reach into the millions in plaintiff-friendly venues if causation is established and punitive damages are awarded. The settlement value serves as a floor for mediation — any reasonable settlement offer on an opt-out case should account for what the plaintiff would have received in the class.
The lawyers who negotiated the settlement have said the Supreme Court’s ruling vindicates their decision to make a deal and lock in funds for cancer victims before the ruling came. They are right in one sense: people who stayed in the class have a guaranteed recovery that does not depend on surviving the preemption defense. But people who opted out took a calculated risk, and some of them will still win — on different theories, with different proof, in front of different juries.
Bayer and Monsanto: Who You Are Really Suing
The corporate structure behind Roundup is a story of acquisition and inherited liability. Bayer AG — the German pharmaceutical and chemical giant — acquired Monsanto Company in 2018. Monsanto was the original manufacturer and distributor of Roundup. It designed the product formulation, controlled the labeling and marketing decisions, and developed the safety dossier submitted to the EPA. Bayer, as the acquiring parent, bears successor liability for Monsanto’s product decisions.
What this means for your case: the defendant is deep-pocketed and collectible. Bayer’s global revenue supports full collectibility of any judgment or settlement. This is not a situation where the defendant is insolvent, judgment-proof, or hidden behind a bankruptcy shell — unlike some mass-tort defendants. Bayer is paying the $7.25 billion settlement from its own resources, and any individual verdict that survives appeal is collectible from a company with the assets to pay it.
But it also means that the internal corporate knowledge that matters most — what Monsanto’s scientists knew about glyphosate and cancer, and when they knew it — lives inside a company that is now a subsidiary of a German parent. Discovery in the surviving cases will target Monsanto’s internal testing records, corporate communications, and scientific assessments, much of which was generated years or decades before the Bayer acquisition. Internal corporate knowledge of glyphosate carcinogenicity studies is a primary discovery target, and documents showing what the company knew about cancer risk signals — and when — fuel both the misrepresentation theory and the punitive-damages narrative.
Potential retail and intermediate distributors in the chain of distribution may also face strict liability claims under state product liability law, though practical recovery is typically pursued against the manufacturer. Whether distributor claims survive the preemption analysis is an open question that depends on the specific theory pleaded against them.
The Science Behind the Fight: IARC vs. EPA
The tension at the heart of every Roundup case is a disagreement between two authoritative bodies about whether glyphosate causes cancer.
In 2015, the International Agency for Research on Cancer — the World Health Organization’s specialized cancer research arm — classified glyphosate as “probably carcinogenic to humans” (Group 2A). This classification was based on a review of scientific evidence by an international panel of experts. It did not say glyphosate definitely causes cancer — it said the evidence was strong enough to place it in the “probably” category, alongside other substances with limited but concerning human evidence and sufficient animal evidence.
The EPA reached a different conclusion. Under FIFRA authority, the EPA determined that glyphosate is “not likely to be carcinogenic to humans.” This is the determination the Supreme Court deferred to in its preemption analysis.
These two positions are not equivalent. IARC conducts hazard identification — it asks whether a substance has the potential to cause cancer. EPA conducts risk assessment — it weighs potential harm against expected exposure levels and regulatory considerations. The Supreme Court’s ruling did not resolve this scientific disagreement. It resolved a legal question: which federal agency’s determination controls for preemption purposes. The answer is the EPA’s, because FIFRA gives the EPA authority over pesticide labeling.
But for the surviving claims, the scientific fight is still live. Plaintiffs in negligence, misrepresentation, and design-defect cases can still present the IARC classification, the underlying scientific studies, and expert testimony on general and specific causation. They can still argue that the EPA’s determination was wrong, or incomplete, or influenced by industry-submitted data. What they cannot do is argue that the label should have carried a cancer warning — because the Supreme Court has said that claim is preempted.
Expert selection is now the make-or-break factor in surviving Roundup cases. Plaintiffs need board-certified oncologists and epidemiologists who can opine on specific causation without relying on the label-warning theory. They need toxicologists who can explain why the EPA’s regulatory finding does not equate to scientific consensus. And they need to be prepared for defense experts who will point to the EPA’s determination and the Supreme Court’s ruling as evidence that the product is safe.
The Medicine: Non-Hodgkin Lymphoma
Non-Hodgkin lymphoma is a cancer that begins in the lymphatic system — the body’s network of lymph nodes, vessels, and organs that helps fight infection. It occurs when white blood cells called lymphocytes develop abnormalities that cause them to multiply uncontrollably. There are many subtypes of NHL, and the subtype matters for both treatment and prognosis.
Treatment depends on the subtype and stage but commonly includes chemotherapy, radiation therapy, immunotherapy, and in some cases stem cell transplants. Lifetime treatment costs frequently exceed several hundred thousand dollars depending on the disease subtype and treatment intensity. Ongoing oncological monitoring continues for years — sometimes for life — because NHL can relapse.
The economic damages in a Roundup case include past and future medical costs: chemotherapy, radiation, immunotherapy, stem cell transplant costs, ongoing oncological monitoring, and lost earning capacity. The non-economic damages encompass physical pain, emotional distress, loss of quality of life, and the psychological burden of a cancer diagnosis attributed to a product the person used regularly — sometimes for decades — without any idea it might be dangerous.
For families who have lost someone to NHL, survival and wrongful death claims apply. The applicable state’s survival statute governs recovery for the decedent’s pre-death damages — the pain, suffering, and medical costs experienced between diagnosis and death. Wrongful death damages compensate the surviving family for their losses. The specific split between survival and wrongful death damages varies by state, and in Missouri, the framework for these claims should be confirmed with current state-specific rules.
If your family lost someone to non-Hodgkin lymphoma and you believe Roundup exposure was a contributing cause, the wrongful death claim process is a separate legal path that may be available alongside or instead of the class settlement — depending on whether you opted out.
What Your Case Is Worth After the Ruling
Every case is different, and we will not pretend otherwise. What we can give you is the honest framework — the factors that drive value and the ranges that reflect the new reality.
For cases in the class settlement: the settlement matrix under the $7.25 billion structure provides a floor for individual recoveries. Per-plaintiff values vary significantly based on exposure duration, cancer subtype, age at diagnosis, and treatment costs. Lower-tier claims — shorter exposure, less aggressive disease subtype — may recover in the tens of thousands. Higher-tier claims with prolonged occupational exposure and severe disease could reach several hundred thousand through the settlement structure. These are not guarantees — they are the framework the settlement uses, and final amounts depend on the matrix details that will be applied at final approval.
For individual opt-out cases on surviving theories: the ceiling is higher but the probability of success has decreased. Individual litigation on negligence, design defect, and misrepresentation carries the potential for multi-million-dollar verdicts in plaintiff-friendly venues — if causation is established and punitive damages are awarded. But the deflating factors are real: the loss of the easiest liability theory, the EPA regulatory validation that the defense will exploit at every stage, and the uncertainty over whether Bayer will successfully extend the preemption argument to the remaining claims.
The overturned $1.25 million Missouri verdict provides a reference point — it represented the lower-to-middle range of prior Roundup verdicts on the now-preempted failure-to-warn theory. Pre-ruling verdicts in comparable cases reached substantially higher figures, though those often relied on the failure-to-warn theory that is no longer available. Surviving-theory verdicts may differ materially depending on jurisdiction and proof strength.
Punitive damages remain theoretically available on the surviving negligence and misrepresentation theories — if plaintiffs can demonstrate that Bayer acted with conscious disregard for known safety risks. However, the preemption ruling weakens the punitive narrative by validating the EPA’s safety finding. The defense will argue: how can the company have acted with conscious disregard when the federal regulator said the product is safe? The counter-argument: the company’s own internal science may have raised concerns the EPA never saw, and the misrepresentation claim targets what the company told the public versus what it knew internally.
Missouri follows pure comparative fault principles, which means your recovery is reduced by your percentage of fault but is never completely barred — even if you were partly responsible for your own exposure. Missouri has also historically permitted uncapped damages in toxic tort cases, which contributed to plaintiff verdicts there and makes Missouri a potentially favorable venue for individual litigation on the surviving theories.
The Evidence That Wins a Surviving Case
With failure-to-warn gone, the evidence that matters has shifted. The label is no longer the battleground. What the company knew, what it said, and how it tested are the new front lines. Here is what exists, who holds it, and how fast it can disappear.
Your exposure history. Purchase receipts, employment records, and usage logs establish specific causation by documenting the duration, frequency, and intensity of your Roundup use. This is critical for distinguishing your individual case from the broad class and for proving significant exposure above background levels. These records degrade over time — receipts fade, employers purge old files — but they are not subject to rapid electronic destruction. Moderate preservation risk. Compile them early.
Your medical records. Pathology reports, treatment history, diagnostic imaging, and oncologist notes confirm your NHL diagnosis, subtype classification, treatment course, prognosis, and the causation timeline linking disease onset to your exposure period. Medical records are retained per regulatory requirements and are at low to moderate risk of loss. They should be compiled early to establish the temporal relationship between your Roundup use and your diagnosis.
Internal Monsanto and Bayer corporate documents. These are the gold for the surviving claims. They support negligence and misrepresentation by revealing what the company knew about cancer risk signals and when — and whether there were discrepancies between public safety claims and internal scientific concerns. Many of these documents are already subject to extensive discovery in prior cases, but they are newly relevant to the surviving theories. Document preservation holds are in place from existing litigation, but additional custodian searches may be needed for employees and departments not previously targeted. Moderate preservation risk.
EPA registration correspondence and regulatory filings. These establish the regulatory framework for the preemption defense and may reveal internal EPA deliberations about carcinogenicity evidence. Understanding the regulatory record helps counter Bayer’s preemption arguments on remaining claims. These are federal regulatory records that are permanently retained and publicly accessible. Low risk.
Marketing and advertising materials for Roundup. These directly support the surviving misrepresentation theory by documenting safety representations made to consumers beyond the product label. Historical marketing materials — advertisements, promotional brochures, website content, public statements by company officials — may be archived, but corporate rebranding and document retention policies may have eliminated some materials. Moderate risk. Preserve and demand early.
If you believe you have a Roundup case, the toxic tort claim process requires building this evidence package methodically — and the surviving theories make the corporate-document discovery more important, not less.
How Bayer’s Lawyers Will Fight the Surviving Claims
Bayer’s defense strategy did not end with the Supreme Court victory. It shifted. Here is what the company’s lawyers will do next — and how each play is countered.
Play 1: Extend preemption to design defect and negligence. Bayer will argue that the Supreme Court’s logic — that the EPA’s approval of Roundup preempts state-law claims — should extend beyond failure-to-warn to design-defect and negligence claims. The argument: if the EPA approved the product as formulated, how can a state jury say the design was defective? The counter: the EPA’s approval under FIFRA is a labeling and registration decision, not a finding that the product is defect-free under every state’s tort law. The EPA does not conduct the kind of risk-utility analysis that a design-defect jury performs. The Supreme Court’s ruling was about labeling requirements, not about whether state tort law is preempted in its entirety. This is the next battleground, and it will be fought motion by motion in federal and state courts.
Play 2: Exploit the EPA finding at every stage. Bayer will put the EPA’s “not likely to be carcinogenic” determination in front of every jury, in every motion, at every opportunity. The defense will frame regulatory compliance as a shield: the federal government said this product is safe, so how can the company be liable? The counter: regulatory compliance is a floor, not a ceiling. The FDA device and drug preemption cases make clear that meeting a federal minimum is not the same as being safe — and a jury is entitled to hear evidence that the EPA’s determination was based on industry-submitted data, that IARC reached a different conclusion, and that the company’s own scientists may have had concerns the EPA never evaluated. Voir dire must address the EPA finding directly, because the defense will use it from day one.
Play 3: Challenge general and specific causation. With failure-to-warn gone, the surviving claims require deeper expert proof on whether glyphosate causes NHL (general causation) and whether it caused THIS plaintiff’s NHL (specific causation). Bayer will file Daubert motions to exclude plaintiff experts, arguing that the science does not support a causal link. The counter: the IARC classification, the underlying epidemiological studies, and the plaintiff’s specific exposure history — dose, duration, frequency — combined with expert testimony from board-certified oncologists and epidemiologists who can opine on specific causation without relying on the label theory. Expert selection is now the make-or-break factor.
Play 4: Push the settlement as the better alternative. Bayer will point to the $7.25 billion settlement and argue that opt-out plaintiffs are gambling against a Supreme Court ruling that has already eliminated their strongest claim. The counter: the settlement matrix may significantly undervalue cases with strong exposure evidence, severe disease, and clear corporate-knowledge documents. For the right plaintiff — prolonged occupational exposure, aggressive NHL subtype, and a jurisdiction with favorable tort law — individual litigation may produce a substantially higher recovery than the settlement matrix, even on the surviving theories alone.
How a Surviving Case Is Built — Step by Step
Here is how a Roundup case on the surviving theories is actually constructed, from the day you call to the day a number is on the table.
Week one: the preservation letter goes out. The day you call, a written demand goes to Bayer’s counsel and Monsanto’s records custodians ordering them to freeze every relevant document — internal testing records, corporate communications, marketing materials, scientific assessments, and post-market surveillance data. This is not a formality. It is the legal step that converts routine document destruction into sanctionable spoliation if the company lets evidence die after receiving the demand. The surviving theories make corporate-document discovery more important than ever, and the preservation letter is what keeps that evidence alive.
Weeks two through four: the exposure and medical record package. We compile your complete Roundup exposure history — when you used it, how often, how much, for how many years, in what setting (residential, occupational, agricultural). We pull your complete medical file — pathology reports confirming NHL diagnosis and subtype, treatment records, oncologist notes, diagnostic timeline. These two packages together establish the foundation: significant exposure and a cancer diagnosis temporally connected to that exposure.
Months one through three: expert recruitment. For the surviving claims, expert selection is the case. We retain board-certified oncologists who can opine on specific causation — that your NHL was caused by glyphosate exposure, not by random chance. We retain epidemiologists who can explain the IARC classification and the underlying studies. We retain toxicologists who can explain why the EPA’s regulatory finding does not equate to scientific consensus — and why the agency’s risk-assessment framework is different from the question a jury must answer.
Months three through six: discovery and depositions. Written discovery goes to Bayer and Monsanto — interrogatories, document requests, requests for admission. We demand the internal testing protocols, the corporate communications about glyphosate and cancer, the marketing materials, the post-market surveillance data, and the documents showing what the company knew about the IARC classification and how it responded. Then come the depositions — where Monsanto’s scientists and executives explain the company’s choices under oath. The gap between what they told the public and what they knew internally is the misrepresentation case.
Months six through twelve: the number gets built. A life-care planner prices out every treatment, every medication, every follow-up visit, every future medical need — projected across your life expectancy. A forensic economist reduces that stream to present value and calculates lost earning capacity. Non-economic damages — pain, suffering, loss of quality of life — are priced against the backdrop of comparable verdicts in the venue. If the corporate documents show conscious disregard, punitive damages enter the calculation. The number that emerges is not a wish — it is an arithmetic problem built from provable components.
Mediation and trial. Most cases settle. The settlement value of an opt-out case should use the class settlement matrix as a floor — any reasonable mediation offer should account for what you would have received in the class. But if the offer does not reflect the full value of the provable harm, the case goes to trial. In Missouri, a jury of your neighbors decides — and Missouri’s pure comparative fault rule means your own share of fault reduces, but never erases, your recovery.
Missouri: Why This State Is the Epicenter
The overturned $1.25 million verdict came from a Missouri courtroom. The $7.25 billion class settlement is proceeding through Missouri state court. And Missouri has historically been one of the most significant venues for mass tort litigation in the United States — with St. Louis City and St. Louis County producing substantial verdicts in pharmaceutical and chemical exposure cases over the years.
Missouri follows pure comparative fault principles. This means that even if you were partly at fault — for example, if you used Roundup without protective equipment — your recovery is reduced by your percentage of fault but never completely barred. In a state that follows a modified comparative fault rule with a 50% or 51% bar, a plaintiff who is found to be more than half at fault recovers nothing. In Missouri, that same plaintiff would still recover — just reduced by their share.
Missouri has also historically permitted uncapped damages in toxic tort cases. This means there is no statutory ceiling on non-economic damages (pain and suffering) or punitive damages in these types of cases — unlike some states that cap non-economic damages in product liability or medical malpractice cases. This does not mean damages are unlimited in practice — juries and judges still apply reason — but it means the legal framework does not impose an artificial ceiling that would limit recovery in a strong case.
The proposed class settlement’s presence in Missouri state court makes that jurisdiction the procedural epicenter for the nationwide Roundup litigation landscape. The judge who granted initial approval in March 2026 will consider final approval at a future hearing, and the objections that have been filed will be ruled on in that Missouri courtroom.
For individual cases on the surviving theories, Missouri’s plaintiff-friendly reputation in certain jurisdictions — particularly St. Louis City and St. Louis County — may make it a strategically favorable venue, depending on where the plaintiff lives and where the exposure occurred. Venue strategy is case-specific and should be evaluated with counsel who understands the nuances of Missouri’s tort system.
Your Deadline — and Why It May Be Different Than You Think
Missouri’s statute of limitations for personal injury actions is generally five years. In toxic tort cases, however, the clock may not start on the date of exposure — it may start when you discovered, or reasonably should have discovered, that your injury was caused by the product. This is the discovery rule, and it is particularly important in Roundup cases because the latency period between glyphosate exposure and a non-Hodgkin lymphoma diagnosis can be years or even decades.
What this means: if you were exposed to Roundup in the 2000s but were not diagnosed with NHL until 2023, and you did not know — and had no reason to know — that your cancer was connected to Roundup until you heard about the litigation or the IARC classification, the clock on your deadline may have started much later than the date of your exposure. A diagnosis you only recently received may be the start of your window, not the end of it.
But this is not a guarantee. The discovery rule’s application varies by state and by the specific facts of your case. Some states impose an outer deadline — a statute of repose — that can cut off a claim even before discovery. The only safe approach is to talk to a lawyer who can evaluate your specific timeline and confirm the controlling deadline for your jurisdiction.
If you are in the class settlement, your claim is being resolved through the settlement structure and the individual SOL may not be your immediate concern. If you opted out, or if you are considering a new filing, the SOL is critical — and waiting could cost you the case entirely.
The First Steps: What to Do Right Now
If you have a pending Roundup case, think you might have one, or lost a family member to non-Hodgkin lymphoma and used Roundup for years:
Determine your settlement status. If you were part of the class, you need to understand what the settlement matrix means for your specific situation — your exposure duration, your cancer subtype, your treatment costs. If you opted out, you need an immediate evaluation of your case on the surviving theories. The opt-out deadline has passed, but the analysis of what your case is worth on negligence, misrepresentation, and design defect is what determines whether the opt-out was the right call.
Compile your exposure history. Write down every job, every season, every year you used Roundup. Where you bought it. How often. How much. What you were doing — residential lawn care, commercial landscaping, agricultural work, park maintenance, railroad work, utility work. Every detail of duration, frequency, and intensity is a piece of the specific-causation proof.
Compile your medical records. Your pathology report, your treatment history, your oncologist’s notes, your diagnostic timeline. These establish the injury and its temporal connection to your exposure.
Do not sign anything from Bayer or any insurance representative without speaking to a lawyer first. If you receive a settlement offer, a release form, or a request for a recorded statement, do not respond. These communications are designed to resolve the company’s exposure — not yours.
Call us. The consultation is free. We work on contingency — 33.33% before trial, 40% if the case goes to trial. We do not get paid unless we win your case. And the call costs you nothing but the time it takes to tell us what happened.
Frequently Asked Questions
Is my Roundup case over because of the Supreme Court ruling?
No. The Supreme Court eliminated the failure-to-warn theory — the claim that Bayer should have put a cancer warning on the label. But three other legal theories survived: negligence (the company failed to act with reasonable care in testing and marketing), misrepresentation (the company made false safety claims beyond the label), and design defect (the product itself was unreasonably dangerous). These are harder to prove than failure-to-warn was, but they are alive and being pursued. If you are in the class settlement, your case is being resolved through the settlement structure regardless of the ruling.
Can I still file a new Roundup lawsuit?
Potentially, yes — but the path is different now. A new lawsuit would proceed on the surviving theories (negligence, misrepresentation, design defect), not on failure-to-warn. The statute of limitations in your state — and whether the discovery rule applies — will determine whether your filing is timely. In Missouri, the personal injury statute of limitations is generally five years, but the discovery rule may mean the clock starts later than you think. You need to talk to a lawyer to evaluate your specific timeline.
What if I already opted out of the $7.25 billion settlement?
You kept your individual case. That decision was made before the Supreme Court ruled, so you did not know failure-to-warn would be preempted. Your case now proceeds on the surviving theories. The road is harder, but the ceiling is higher — individual litigation can produce substantially larger recoveries than the settlement matrix in the right circumstances. Your case should be evaluated immediately on the surviving theories to determine whether the opt-out was the right strategic call and what the next steps are.
What if I missed the June 4 opt-out deadline?
If you did not opt out by June 4, you are in the class. Your case will be resolved through the settlement structure, and you will receive compensation according to the settlement matrix. You will not face the risk of the Supreme Court ruling, but you also will not have the opportunity for a higher individual recovery through trial. The settlement is not yet final — the Missouri judge will consider final approval at a future hearing, and objections have been filed — but if it is approved, the settlement terms will govern your recovery.
How much is my Roundup case worth now?
It depends on your specific facts and whether you are in the class or pursuing individual litigation. In the class settlement, per-plaintiff values vary based on exposure duration, cancer subtype, age at diagnosis, and treatment costs — lower-tier claims may recover in the tens of thousands, higher-tier claims with prolonged occupational exposure and severe disease could reach several hundred thousand. In individual litigation on surviving theories, the range is wider — from lower recoveries in weaker cases to potentially multi-million-dollar verdicts in strong cases in favorable venues. No lawyer can guarantee a specific number without evaluating your exposure history, medical records, and jurisdiction.
What legal theories still work after the ruling?
Three theories survived: negligence (Bayer failed to exercise reasonable care in designing, testing, and marketing Roundup), misrepresentation (Bayer made false safety claims in marketing and public statements beyond the product label), and design defect (Roundup’s formulation was unreasonably dangerous). Each requires different proof — negligence targets internal testing and corporate knowledge, misrepresentation targets the gap between public claims and internal science, and design defect targets the product formulation itself. Bayer is expected to argue that the preemption logic should extend to design-defect claims, creating a new legal battleground.
How long do I have to file a Roundup claim in Missouri?
Missouri’s personal injury statute of limitations is generally five years. However, in toxic tort cases, the discovery rule may apply — meaning the clock may start when you discovered, or should have discovered, that your cancer was connected to Roundup, not when you were exposed. Because the latency between glyphosate exposure and NHL diagnosis can be years or decades, the discovery rule may give you more time than you think. But this is not automatic — the specific facts of your case and the current state of Missouri law on discovery-rule accrual must be evaluated by a lawyer. Do not assume you have plenty of time, and do not assume you are too late. Call and find out.
Will Bayer try to get the remaining claims dismissed too?
Yes. Bayer is expected to argue that the Supreme Court’s preemption logic should extend to design-defect and potentially negligence claims, on the theory that the EPA’s approval of Roundup should shield the company from all state-law product-liability claims — not just failure-to-warn. Whether that argument succeeds is an open question. The Supreme Court’s ruling was specifically about labeling requirements under FIFRA, not about whether all state tort claims are preempted. But the defense will push the argument as far as the courts will allow. This is one of the most important unresolved legal issues in the Roundup litigation, and it is a reason to move quickly — before the legal landscape narrows further.
What evidence do I need for a surviving Roundup claim?
Your exposure history (when, how much, how often you used Roundup), your medical records (pathology confirming NHL, treatment history, diagnostic timeline), and — through discovery — Monsanto’s internal corporate documents showing what the company knew about glyphosate and cancer risk, and when. The surviving claims make corporate-document discovery more important, not less, because the case is now about what the company did and said internally, not just about what the label omitted. Marketing and advertising materials are also critical for the misrepresentation theory.
Should I join the class settlement or pursue an individual case?
If the June 4 opt-out deadline has passed, that decision may already be made for you. If you are in the class, you are in the class. If you opted out, you are on the individual path. For anyone considering a new claim, the class settlement may accept future claimants — the deal was designed to cover people who develop cancer in the future — but the specific terms and deadlines for future claimants should be confirmed with counsel. The right choice depends on the strength of your exposure evidence, the severity of your disease, your jurisdiction, and your risk tolerance. There is no one-size-fits-all answer, and anyone who tells you otherwise is not giving you honest advice.
Why People Call Attorney911
When the Supreme Court ruling came down on June 25, 2026, a lot of people with Roundup cases felt the ground shift under them. Some were told by other lawyers that their cases were over. Some were told to take whatever the settlement offered and be grateful. We do not practice that way.
We handle toxic tort and catastrophic injury cases with the understanding that a legal setback is terrain to be navigated, not a reason to surrender. The Supreme Court took away one theory. Three survived. Our job is to evaluate whether your case is strong enough on those surviving theories to pursue — and to tell you honestly if it is not. If we are not the right fit for your case, we will tell you. But if your exposure was significant, your diagnosis is clear, and your case has merit on the remaining claims, we will fight for every dollar the law allows.
Ralph Manginello has spent 27+ years in courtrooms, including federal court. He is a journalist who became a lawyer — which means he knows how to find the story the documents tell, and how to tell it to a jury. He is admitted to the U.S. District Court for the Southern District of Texas and has been trying cases since 1998. Ralph’s background is the work of a person who hates losing and does not take a case he does not believe in.
Lupe Peña spent years inside a national insurance-defense firm — the rooms where adjusters and their software decided how to deny, delay, and devalue claims exactly like yours. He knows how claims are valued from the inside, how the defense picks its experts, and where the pressure points are. Now he sits on your side of the table. He conducts full consultations in Spanish without an interpreter. Lupe’s experience is the insider advantage — the knowledge of how the other side operates, turned to your benefit.
We take cases in Missouri, working with local counsel and pro hac vice admission where required. We do not claim an office in Missouri, and we will not pretend to something we are not. What we bring is the work — the evidence package, the expert recruitment, the corporate-document discovery, the trial preparation — and the willingness to tell you the truth about what your case is worth after the ruling changed the landscape.
We work on contingency. The fee is 33.33% before trial and 40% if the case goes to trial. We do not get paid unless we win your case. The consultation is free, and it is confidential. We have live staff available 24/7 — not an answering service, not a robot, not a callback queue. Someone picks up the phone.
Past results depend on the facts of each case and do not guarantee future outcomes. The firm has recovered more than $50 million for clients across its practice — including a $5M+ brain-injury settlement, a $3.8M+ amputation settlement, and a $2.5M+ truck-crash recovery. Those results came from specific facts in specific cases, and we will not promise you a number. What we promise is the work.
If you used Roundup and developed non-Hodgkin lymphoma — or if you lost a family member who did — the Supreme Court ruling changed the fight, but it did not end it. Call us at 1-888-ATTY-911. The call is free. The consultation is free. And the answer to whether your case survives starts with a conversation, not a headline.
Hablamos Español. Lupe conducts full consultations in Spanish, and our staff is bilingual. If your family communicates in Spanish, you will not need an interpreter to understand your rights.
1-888-ATTY-911. Free consultation. No fee unless we win.